Project description DEENESFRITPL Biomarkers of allergen immunotherapy Allergic rhinitis (AR) is an allergic disease caused when the immune system overreacts to airborne particles such as pollen and dust mites. Allergen immunotherapy (AIT) is a type of treatment for allergic disorders that involves injecting small amounts of an allergen extract under the skin over a period of time to reduce the severity of symptoms by desensitising the patient’s immune system to the allergen. Funded by the Marie Skłodowska-Curie Actions programme, the PRE-BIT project aims to study the phenotypes of B cells modified by AIT and to generate biomarkers that predict the therapy’s outcome. Researchers will analyse the B cell compartment in AR patients before and after AIT and identify biomarkers associated with AIT efficacy. Show the project objective Hide the project objective Objective Allergic rhinitis (AR) is one the more prevalent respiratory allergic disease affecting 20-30% of the global population. The inflammatory process is mediated by eosinophil infiltration and IgE secreted by plasma cells. IgE is a key component in allergies so understanding IgE production and its inhibition is important for treating these diseases. Allergen immunotherapy (AIT) is the only treatment that targets the etiology of allergic diseases. However, the efficacy of the treatment reaches 70-80% in the best scenarios (lower for food allergy), it has a high cost, and most important, prediction of the effectiveness of the treatment is not possible with actual biomarkers. In this proposal the candidate seeks to better understand the phenotypes of B cells, key cells implicated in allergy that are modified with AIT. The knowledge generated by this study will provide biomarkers of AIT prognosis and even predict the outcome of the therapy by analyzing the B cell compartment in patients candidate for AIT.Using very innovative approaches, we will analyze the B cell repertoire involved in the resolution of AR through AIT. B cell repertoire will be analyzed in bulk before and after AIT. In addition, antigen specific B cells will be immortalized so the antibody sequence as well as reactivity can be studied. Moreover, we will perform an ex vivo class switch assay that could potentially predict the outcome of AIT using cytokine microenvironments like those produced by the therapy and or the pathogenic situations. B cell switching from IgD/M or IgG1 to IgG2/4 appears to be a critical step in the effectiveness in AIT because IgE memory resides in the IgG compartment. We will use AR to house dust mite patients as a model as it is one of the most prevalent allergic diseases. Fields of science medical and health sciencesclinical medicineallergologymedical and health sciencesbasic medicineimmunologyimmunotherapy Keywords Allergy Allergic Rhinitis B cells IgE Immunotherapy Dermatophagoides pteronyssinus tolerance IgG2 IgG4 Programme(s) HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA) Main Programme Topic(s) HORIZON-MSCA-2022-PF-01-01 - MSCA Postdoctoral Fellowships 2022 Call for proposal HORIZON-MSCA-2022-PF-01 See other projects for this call Funding Scheme MSCA-PF - MSCA-PF Coordinator FUNDACION PUBLICA ANDALUZA PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD Net EU contribution € 181 152,96 Address Calle severo ochoa 35, parque tecnologico de andalucia 29580 Malaga Spain See on map Region Sur Andalucía Málaga Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00
